Treatment strategies for ADHD: an evidence-based guide to select optimal treatment.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
23
12
2017
accepted:
14
05
2018
revised:
20
04
2018
pubmed:
30
6
2018
medline:
4
12
2019
entrez:
30
6
2018
Statut:
ppublish
Résumé
Attention-deficit/hyperactivity disorder (ADHD) is a common and impairing disorder affecting children, adolescents, and adults. Several treatment strategies are available that can successfully ameliorate symptoms, ranging from pharmacological to dietary interventions. Due to the increasing range of available options, an informed selection or prioritization of treatments is becoming harder for clinicians. This review aims to provide an evidence-based appraisal of the literature on ADHD treatment, supplemented by expert opinion on plausibility. We outline proposed mechanisms of action of established pharmacologic and non-pharmacologic treatments, and we review targets of novel treatments. The most relevant evidence supporting efficacy and safety of each treatment strategy is discussed. We review the individualized features of the patient that should guide the selection of treatments in a shared decision-making continuum. We provide guidance for optimizing initiation of treatment and follow-up of patients in clinical settings.
Identifiants
pubmed: 29955166
doi: 10.1038/s41380-018-0116-3
pii: 10.1038/s41380-018-0116-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-408Références
APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.
pubmed: 17541055
pmcid: 17541055
Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204–11.
pubmed: 19252145
pmcid: 19252145
Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387:1240–50.
pubmed: 26386541
pmcid: 26386541
Asherson P, Buitelaar J, Faraone SV, Rohde LA. Adult attention-deficit hyperactivity disorder: key conceptual issues. Lancet Psychiatry. 2016;3:568–78.
pubmed: 27183901
pmcid: 27183901
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1:15020.
pubmed: 27189265
pmcid: 27189265
Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015;2:702–9.
pubmed: 26249301
pmcid: 26249301
Grygiel P, Humenny G, Rebisz S, Bajcar E, Switaj P. Peer rejection and perceived quality of relations with schoolmates among children with ADHD. J Atten Disord. 2014;22:738–51.
pubmed: 25526905
pmcid: 25526905
DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry. 2001;40:508–15.
pubmed: 11349694
pmcid: 11349694
Peasgood T, Bhardwaj A, Biggs K, Brazier JE, Coghill D, Cooper CL, et al. The impact of ADHD on the health and well-being of ADHD children and their siblings. Eur Child Adolesc Psychiatry. 2016;25:1217–31.
pubmed: 27037707
pmcid: 27037707
Galera C, Melchior M, Chastang JF, Bouvard MP, Fombonne E. Childhood and adolescent hyperactivity-inattention symptoms and academic achievement 8 years later: the GAZEL Youth study. Psychol Med. 2009;39:1895–906.
pubmed: 19335935
pmcid: 19335935
Harstad E, Levy S, Committee on Substance Abuse. Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics. 2014;134:e293–301.
pubmed: 24982106
pmcid: 24982106
Molina BSG, Howard AL, Swanson JM, Stehli A, Mitchell JT, Kennedy TM, et al. Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study. J Child Psychol Psychiatry. 2018;59:692–702.
pubmed: 29315559
pmcid: 29315559
Galera C, Messiah A, Melchior M, Chastang JF, Encrenaz G, Lagarde E, et al. Disruptive behaviors and early sexual intercourse: the GAZEL Youth Study. Psychiatry Res. 2010;177:361–3.
pubmed: 20381166
pmcid: 20381166
Caye A, Rocha TB, Anselmi L, Murray J, Menezes AM, Barros FC, et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry. 2016;73:705–12.
pubmed: 27192050
pmcid: 27192050
Meinzer MC, LeMoine KA, Howard AL, Stehli A, Arnold LE, Hechtman L, et al. Childhood ADHD and involvement in early pregnancy: mechanisms of risk. J Atten Disord. 2017. https://doi.org/10.1177/1087054717730610 .
Hechtman L, Swanson JM, Sibley MH, Stehli A, Owens EB, Mitchell JT, et al. Functional adult outcomes 16 years after childhood diagnosis of attention-deficit/hyperactivity disorder: MTA results. J Am Acad Child Adolesc Psychiatry. 2016;55:945–52.
pubmed: 27806862
pmcid: 27806862
Klein RG, Mannuzza S, Olazagasti MA, Roizen E, Hutchison JA, Lashua EC, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 2012;69:1295–303.
pubmed: 23070149
pmcid: 23070149
Biederman J, Monuteaux MC, Mick E, Spencer T, Wilens TE, Silva JM, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36:167–79.
pubmed: 16420713
pmcid: 16420713
Chang Z, Lichtenstein P, D’Onofrio BM, Sjolander A, Larsson H. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry. 2014;71:319–25.
pubmed: 24477798
pmcid: 24477798
Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367:2006–14.
pubmed: 23171097
pmcid: 23171097
Ebejer JL, Medland SE, van der Werf J, Gondro C, Henders AK, Lynskey M, et al. Attention deficit hyperactivity disorder in Australian adults: prevalence, persistence, conduct problems and disadvantage. PLoS ONE. 2012;7:e47404.
pubmed: 23071800
pmcid: 23071800
Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME, et al. ADHD medication and substance-related problems. Am J Psychiatry. 2017;174:877–85.
pubmed: 28659039
pmcid: 28659039
Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385:2190–6.
Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51:990–1002.
pubmed: 23021476
pmcid: 23021476
Excellence NIfC. Attention deficit hyperactivity disorder: the NICE guideline on diagnosis and management of ADHD in children, young people and adults. London: The British Psychological Society and the Royal College of Psychiatrists; 2009.
Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management, Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007–22.
Pliszka S, Issues AWGoQ. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.
pubmed: 17581453
pmcid: 17581453
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines. Third Edition. Toronto, ON: CADDRA; 2011.
Bolea-Alamanac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:179–203.
pubmed: 24526134
pmcid: 24526134
Sonuga-Barke EJ, Coghill D. The foundations of next generation attention-deficit/hyperactivity disorder neuropsychology: building on progress during the last 30 years. J Child Psychol Psychiatry. 2014;55:e1–5.
pubmed: 25399637
pmcid: 25399637
Catala-Lopez F, Hutton B, Nunez-Beltran A, Page MJ, Ridao M, Macias Saint-Gerons D, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS ONE. 2017;12:e0180355.
pubmed: 28700715
pmcid: 28700715
Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203.
pubmed: 26608309
pmcid: 26608309
Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D, et al. Neurofeedback for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry. 2016;55:444–55.
pubmed: 27238063
pmcid: 27238063
Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW, et al. Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54:164–74.
pubmed: 25721181
pmcid: 25721181
Daley D, van der Oord S, Ferrin M, Danckaerts M, Doepfner M, Cortese S, et al. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry. 2014;53:835–47.
pubmed: 25062591
pmcid: 25062591
Riera M, Castells X, Tobias A, Cunill R, Blanco L, Capella D. Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients. Psychopharmacology (Berl). 2017;234:2657–71.
pubmed: 28631099
pmcid: 28631099
Liu Q, Zhang H, Fang Q, Qin L. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials. J Clin Exp Neuropsychol. 2017;39:854–65.
Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60:42–51.
pubmed: 4344946
pmcid: 4344946
Rapport MD, Orban SA, Kofler MJ, Friedman LM. Do programs designed to train working memory, other executive functions, and attention benefit children with ADHD? A meta-analytic review of cognitive, academic, and behavioral outcomes. Clin Psychol Rev. 2013;33:1237–52.
pubmed: 24120258
pmcid: 24120258
Zwi M, Jones H, Thorgaard C, York A, Dennis JA. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2011;12:CD003018.
Storebo OJ, Skoog M, Damm D, Thomsen PH, Simonsen E, Gluud C. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2011;12:CD008223.
Danielson ML, Visser SN, Chronis-Tuscano A, DuPaul GJ. A national description of treatment among United States children and adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2018;192:240–6.
pubmed: 29132817
pmcid: 29132817
Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry. 2005;57:1377–84.
pubmed: 15950011
pmcid: 15950011
Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132–3.
pubmed: 10609822
pmcid: 10609822
Krause KH, Dresel S, Krause J, Kung HF, Tatsch K, Lochmuller H. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate. J Neurol. 2002;249:1116–8.
pubmed: 12420715
pmcid: 12420715
Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry. 2007;62:1059–61.
pubmed: 17511972
pmcid: 17511972
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302:1084–91.
pubmed: 19738093
pmcid: 19738093
Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64:932–40.
pubmed: 17679638
pmcid: 17679638
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry. 2012;169:264–72.
Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J Neurosci. 2012;32:841–9.
pubmed: 3350870
pmcid: 3350870
Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28:S46–53.
Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology. 2006;50:755–60.
pubmed: 16427661
pmcid: 16427661
Arnsten AF. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother. 2010;10:1595–605.
pubmed: 20925474
pmcid: 20925474
Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54:800–5.
pubmed: 14550679
pmcid: 14550679
Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The Development and Well-Being Assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. J Child Psychol Psychiatry. 2000;41:645–55.
pubmed: 10946756
pmcid: 10946756
Schmitt KC, Reith ME. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS ONE. 2011;6:e25790.
pubmed: 22043293
pmcid: 22043293
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry. 2013;70:185–98.
pubmed: 23247506
pmcid: 23247506
Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology. 2009;57:640–52.
pubmed: 19715709
pmcid: 19715709
Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129:397–410.
pubmed: 17448997
pmcid: 17448997
Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51:356–67.
pubmed: 22449642
pmcid: 22449642
Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009;25:2745–54.
pubmed: 19785510
pmcid: 19785510
Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad Med. 2008;120:69–88.
pubmed: 18824827
pmcid: 18824827
Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007;61:694–9.
pubmed: 16893523
pmcid: 16893523
Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43:896–904.
pubmed: 15213591
pmcid: 15213591
Poelmans G, Pauls DL, Buitelaar JK, Franke B. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry. 2011;168:365–77.
pubmed: 21324949
pmcid: 21324949
Udvardi PT, Fohr KJ, Henes C, Liebau S, Dreyhaupt J, Boeckers TM, et al. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain—an in vivo study. Drug Des Devel Ther. 2013;7:1433–46.
pubmed: 24348020
pmcid: 24348020
Song ZM, Abou-Zeid O, Fang YY. alpha2a adrenoceptors regulate phosphorylation of microtubule-associated protein-2 in cultured cortical neurons. Neuroscience. 2004;123:405–18.
pubmed: 14698748
pmcid: 14698748
Schweren LJ, de Zeeuw P, Durston S. MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23:1151–64.
pubmed: 23165220
pmcid: 23165220
Yanofski J. The dopamine dilemma—part II: could stimulants cause tolerance, dependence, and paradoxical decompensation? Innov Clin Neurosci. 2011;8:47–53.
pubmed: 21311708
pmcid: 21311708
Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200:97–106.
pubmed: 22297588
pmcid: 22297588
Su Y, Li H, Chen Y, Fang F, Xu T, Lu H, et al. Remission rate and functional outcomes during a 6-month treatment with osmotic-release oral-system methylphenidate in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2015;35:525–34.
pubmed: 26267421
pmcid: 26267421
Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, et al. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. J Child Adolesc Psychopharmacol. 2012;22:215–25.
pubmed: 22537358
pmcid: 22537358
Bruxel EM, Akutagava-Martins GC, Salatino-Oliveira A, Contini V, Kieling C, Hutz MH, et al. ADHD pharmacogenetics across the life cycle: new findings and perspectives. Am J Med Genet B, Neuropsychiatr Genet. 2014;165B:263–82.
Myer NM, Boland JR, Faraone SV. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry. 2017;00:1–8 (epub ahead of print).
Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82:1241–8.
pubmed: 18485328
pmcid: 18485328
Johnson KA, Barry E, Lambert D, Fitzgerald M, McNicholas F, Kirley A, et al. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. J Child Adolesc Psychopharmacol. 2013;23:655–64.
pubmed: 24350812
pmcid: 24350812
Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology. 2009;57:731–3.
pubmed: 19733552
pmcid: 19733552
Brown JT, Bishop JR. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Pharmacogenomics. 2015;16:1513–20.
pubmed: 26314574
pmcid: 26314574
Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46:242–51.
pubmed: 17242628
pmcid: 17242628
Mick E, McGough JJ, Middleton FA, Neale B, Faraone SV. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:466–72.
pubmed: 21130132
pmcid: 21130132
Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B, Neuropsychiatr Genet. 2008;147B:1412–8.
Pagerols M, Richarte V, Sánchez-Mora C, Rovira P, Soler Artigas M, Garcia-Martínez I, et al. Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder. Sci Rep. 2018;8. https://www.nature.com/articles/s41598-018-20194-7 .
Pharmacogenetic Psychiatry/ADHD Report. 2017. http://www.alphagenomix.com/psychiatry-adhd/ .
ADHD & Genetics. 2017. https://salusgenetics.com/adhd/ .
BiogeniQ Launches a Pharmacogenetic Test Enabling Patients Diagnosed with ADHD to Guide Their Treatment Based on Their Genetics. 2017. https://blog.biogeniq.ca/en/articles/biogeniq-becomes-the-first-canadian-company-that-uses-a-genetic-test-to-guide-treatment-of-adhd .
Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016;21:872–84.
pubmed: 27217152
pmcid: 27217152
Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26:875–97.
pubmed: 28258319
pmcid: 28258319
Maia CR, Cortese S, Caye A, Deakin TK, Polanczyk GV, Polanczyk CA, et al. Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD. J Atten Disord. 2017;21:3–13.
pubmed: 25501355
pmcid: 25501355
Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. Curr Med Res Opin. 2014;30:1673–85.
pubmed: 24627974
pmcid: 24627974
Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011;11:176.
pubmed: 22074258
pmcid: 22074258
Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754–63.
pubmed: 20051220
pmcid: 20051220
Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T. 2009;34:678–94.
pubmed: 20140141
pmcid: 20140141
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48:884–93.
pubmed: 19625978
pmcid: 19625978
Charach A, Carson P, Fox S, Ali MU, Beckett J, Lim CG. Interventions for preschool children at high risk for ADHD: a comparative effectiveness review. Pediatrics. 2013;131:e1584–604.
pubmed: 23545375
pmcid: 23545375
Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50:9–21.
pubmed: 21156266
pmcid: 21156266
Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002;22:468–73.
pubmed: 12352269
pmcid: 12352269
Kambeitz J, Romanos M, Ettinger U. Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Pharmacogenomics J. 2014;14:77–84.
pubmed: 23588108
pmcid: 23588108
King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006;10:iii–iv.
pubmed: 16796929
pmcid: 16796929
Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev. 2008;28:783–800.
pubmed: 18068284
pmcid: 18068284
Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord. 2013;43:2435–41.
pubmed: 23468071
pmcid: 23468071
Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;2:CD009996.
pubmed: 26844979
pmcid: 26844979
Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24:24–9.
pubmed: 14709943
pmcid: 14709943
Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011;25:157–69.
pubmed: 21254791
pmcid: 21254791
Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database Syst Rev. 2011;6:CD007813.
Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol. 2009;23:733–44.
pubmed: 18562416
pmcid: 18562416
Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed. 2006;8:4.
pubmed: 17415287
pmcid: 17415287
Groenman AP, Schweren LJ, Dietrich A, Hoekstra PJ. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Saf. 2017;16:455–64.
pubmed: 28277842
pmcid: 28277842
Shaw P. Quantifying the benefits and risks of methylphenidate as treatment for childhood attention-deficit/hyperactivity disorder. JAMA. 2016;315:1953–5.
pubmed: 27163984
pmcid: 27163984
Hoekstra PJ, Buitelaar JK. Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed? Eur Child Adolesc Psychiatry. 2016;25:339–40.
pubmed: 27021055
pmcid: 27021055
Gerlach M, Banaschewski T, Coghill D, Rohde LA, Romanos M. What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder? Atten Defic Hyperact Disord. 2017;9:1–3.
pubmed: 28168407
pmcid: 28168407
Luan R, Zhiling M, Yue F, He S. Efficacy and tolerability of different interventions in children and adolescents with attention deficit hyperactivity disorder. Front Psychiatry. 2017;8:1–15.
Handen BL, Aman MG, Arnold LE, Hyman SL, Tumuluru RV, Lecavalier L, et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015;54:905–15.
pubmed: 26506581
pmcid: 26506581
Atomoxetine ADHD and Comorbid MDD Study Group, Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, et al. Efficacy and safety of atomoxetine in adolescents with attenti on-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17:407–20.
Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:1119–27.
pubmed: 17712235
pmcid: 17712235
Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65:1941–9.
pubmed: 16380617
pmcid: 16380617
Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53:153–73.
pubmed: 24472251
pmcid: 24472251
Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1551–9.
pubmed: 10596256
pmcid: 10596256
Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs. 2009;23:21–31.
pubmed: 19621975
pmcid: 19621975
Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:180–8.
pubmed: 18182963
pmcid: 18182963
Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE Jr, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008;47:189–98.
pubmed: 18182964
pmcid: 18182964
Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother. 2016;16:131–44.
pubmed: 26693882
pmcid: 26693882
Butterfield ME, Saal J, Young B, Young JL. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. Psychiatry Res. 2016;236:136–41.
pubmed: 26730446
pmcid: 26730446
Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, et al. A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015;54:916–25.
pubmed: 26506582
pmcid: 26506582
Findling RL, McBurnett K, White C, Youcha S. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24:245–52.
pubmed: 24945085
pmcid: 24945085
Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;10:CD009504.
pubmed: 28965364
pmcid: 28965364
Ng QX. A systematic review of the use of bupropion for attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27:112–6.
pubmed: 27813651
pmcid: 27813651
Stuhec M, Munda B, Svab V, Locatelli I. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord. 2015;178:149–59.
pubmed: 25813457
pmcid: 25813457
Li Y, Gao J, He S, Zhang Y, Wang Q. An evaluation on the efficacy and safety of treatments for attention deficit hyperactivity disorder in children and adolescents: a comparison of multiple treatments. Mol Neurobiol. 2017;54:6655–69.
pubmed: 27738872
pmcid: 27738872
Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2014;9:CD006997.
Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153:1147–53.
Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis. 1995;183:48–50.
pubmed: 7807071
pmcid: 7807071
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, et al. Modafinil for the treatment of attention-deficit/hyperactivity disorder: a meta-analysis. J Psychiatr Res. 2017;84:292–300.
Postmarketing Reviews—Volume 1, Number 1, Fall 2007. 2007. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm115974.htm . Accessed 2007.
FDA Committee Rejects ADHD use for Modafinil. 2006. https://www.npr.org/templates/story/story.php?storyId=5298885 . Accessed 2006.
Koblan KS, Hopkins SC, Sarma K, Jin F, Goldman R, Kollins SH, et al. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology. 2015;40:2745–52.
pubmed: 4864650
pmcid: 4864650
Konofal E, Zhao W, Laouenan C, Lecendreux M, Kaguelidou F, Benadjaoud L, et al. Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014;8:2321–32.
pubmed: 25525331
pmcid: 25525331
Efficacy and Safety of SPN-812 ER in Children With ADHD. 2017. https://clinicaltrials.gov/ct2/show/NCT02633527 . Accessed 2017.
Childress A, Mehrotra S, Gobburu J, McLean A, DeSousa NJ, Incledon B. Single-dose pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate formulation, in healthy adults and in adolescents and children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018;28:10–18.
pubmed: 29039979
pmcid: 29039979
Amiloride Hydrochloride as an Effective Treatment for ADHD. 2017. https://clinicaltrials.gov/ct2/show/NCT01733680 .
A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12–17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD. 2017. https://clinicaltrials.gov/ct2/show/NCT02777931 .
Alcobra to stop testing sole drug for ADHD after study fails. 2017. https://www.reuters.com/article/us-alcobra-study/alcobra-to-stop-testing-sole-drug-for-adhd-after-study-fails-idUSKBN1511M9 . Accessed 2017.
Stocks JD, Taneja BK, Baroldi P, Findling RL. A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. J Child Adolesc Psychopharmacol. 2012;22:102–11.
pubmed: 22372512
pmcid: 22372512
Investigating the Effect of Vortioxetine in Adult ADHD Patients. 2018. https://clinicaltrials.gov/ct2/show/NCT02327013 . Accessed 2018.
The MTA Cooperative Group. Multimodal Treatment Study of children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073–86.
Klein RG. MTA findings fail to consider methodological issues. Arch Gen Psychiatry. 2001;58:1184–7.
pubmed: 11735850
pmcid: 11735850
Pelham WE Jr, Fabiano GA, Waxmonsky JG, Greiner AR, Gnagy EM, Pelham WE 3rd, et al. Treatment sequencing for Childhood ADHD: a multiple-randomization study of adaptive medication and behavioral interventions. J Clin Child Adolesc Psychol. 2016;45:396–415.
pubmed: 26882332
pmcid: 26882332
Fabiano GA, Pelham WE Jr, Coles EK, Gnagy EM, Chronis-Tuscano A, O’Connor BC. A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder. Clin Psychol Rev. 2009;29:129–40.
pubmed: 19131150
pmcid: 19131150
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry. 2013;170:275–89.
pubmed: 23360949
pmcid: 23360949
Safren SA, Sprich S, Mimiaga MJ, Surman C, Knouse L, Groves M, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA. 2010;304:875–80.
pubmed: 20736471
pmcid: 20736471
Philipsen A, Jans T, Graf E, Matthies S, Borel P, Colla M, et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:1199–210.
pubmed: 26536057
pmcid: 26536057
Knouse LE, Teller J, Brooks MA. Meta-analysis of cognitive-behavioral treatments for adult ADHD. J Consult Clin Psychol. 2017;85:737–50.
pubmed: 28504540
pmcid: 28504540
Young Z, Moghaddam N, Tickle A. The efficacy of cognitive behavioral therapy for adults with ADHD: a systematic review and meta-analysis of randomized controlled trials. J Atten Disord. 2016; (epub ahead of print).
Schatz NK, Fabiano GA, Cunningham CE, dosReis S, Waschbusch DA, Jerome S, et al. Systematic review of patients’ and parents’ preferences for ADHD treatment options and processes of care. Patient. 2015;8:483–97.
pubmed: 25644223
pmcid: 25644223
Nafees B, Setyawan J, Lloyd A, Ali S, Hearn S, Sasane R, et al. Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry. 2014;23:1189–200.
pubmed: 24443092
pmcid: 24443092
Fiks AG, Mayne S, Debartolo E, Power TJ, Guevara JP. Parental preferences and goals regarding ADHD treatment. Pediatrics. 2013;132:692–702.
pubmed: 23999959
pmcid: 23999959
Coghill DR, Seth S, Matthews K. A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models. Psychol Med. 2014;44:1989–2001.
pubmed: 24176104
pmcid: 24176104
Vinogradov S, Fisher M, de Villers-Sidani E. Cognitive training for impaired neural systems in neuropsychiatric illness. Neuropsychopharmacology. 2012;37:43–76.
pubmed: 22048465
pmcid: 22048465
Shalev L, Tsal Y, Mevorach C. Computerized progressive attentional training (CPAT) program: effective direct intervention for children with ADHD. Child Neuropsychol. 2007;13:382–8.
pubmed: 17564853
pmcid: 17564853
Klingberg T, Fernell E, Olesen PJ, Johnson M, Gustafsson P, Dahlstrom K, et al. Computerized training of working memory in children with ADHD—a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2005;44:177–86.
Shouse MN, Lubar JF. Operant conditioning of EEG rhythms and ritalin in the treatment of hyperkinesis. Biofeedback Self Regul. 1979;4:299–312.
pubmed: 526475
pmcid: 526475
Sitaram R, Ros T, Stoeckel L, Haller S, Scharnowski F, Lewis-Peacock J, et al. Closed-loop brain training: the science of neurofeedback. Nat Rev Neurosci. 2017;18:86–100.
Arns M, Conners CK, Kraemer HC. A decade of EEG theta/beta ratio research in ADHD: a meta-analysis. J Atten Disord. 2013;17:374–83.
Mayer K, Wyckoff SN, Strehl U. One size fits all? Slow cortical potentials neurofeedback: a review. J Atten Disord. 2013;17:393–409.
pubmed: 23264371
pmcid: 23264371
Moriyama TS, Polanczyk G, Caye A, Banaschewski T, Brandeis D, Rohde LA. Evidence-based information on the clinical use of neurofeedback for ADHD. Neurotherapeutics. 2012;9:588–98.
pubmed: 22930416
pmcid: 22930416
Arns M, de Ridder S, Strehl U, Breteler M, Coenen A. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci. 2009;40:180–9.
pubmed: 19715181
pmcid: 19715181
Watanabe T, Sasaki Y, Shibata K, Kawato M. Advances in fMRI real-time neurofeedback. Trends Cogn Sci. 2017;21:997–1010.
pubmed: 29031663
pmcid: 29031663
Koush Y, Ashburner J, Prilepin E, Sladky R, Zeidman P, Bibikov S, et al. OpenNFT: an open-source Python/Matlab framework for real-time fMRI neurofeedback training based on activity, connectivity and multivariate pattern analysis. NeuroImage. 2017;156:489–503.
pubmed: 28645842
pmcid: 28645842
Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R. Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with ADHD. PLoS ONE. 2017;12:e0169277.
pubmed: 28121994
pmcid: 28121994
Prevatt F, Levrini A. Case study: ADHD coaching with an adolescent. ADHD coaching: a guide for mental health professionals. Washington, DC, US: American Psychological Association; 2015. p. 207–25.
Prevatt F, Yelland S. An empirical evaluation of ADHD coaching in college students. J Atten Disord. 2015;19:666–77.
pubmed: 23509112
pmcid: 23509112
Sibley MH, Graziano PA, Kuriyan AB, Coxe S, Pelham WE, Rodriguez L, et al. Parent-teen behavior therapy+motivational interviewing for adolescents with ADHD. J Consult Clin Psychol. 2016;84:699–712.
pubmed: 27077693
pmcid: 27077693
Goldberg SB, Tucker RP, Greene PA, Davidson RJ, Wampold BE, Kearney DJ, et al. Mindfulness-based interventions for psychiatric disorders: a systematic review and meta-analysis. Clin Psychol Rev. 2018;59:52–60.
Evans S, Ling M, Hill B, Rinehart N, Austin D, Sciberras E. Systematic review of meditation-based interventions for children with ADHD. Eur Child Adolesc Psychiatry. 2018;27:9–27.
Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS ONE. 2015;10:e0116407.
pubmed: 25714373
pmcid: 25714373
Jonsson U, Alaie I, Lofgren Wilteus A, Zander E, Marschik PB, Coghill D, et al. Annual research review: quality of life and childhood mental and behavioural disorders—a critical review of the research. J Child Psychol Psychiatry. 2017;58:439–69.
pubmed: 27709604
pmcid: 27709604
Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017;26:1283–307.
pubmed: 28429134
pmcid: 28429134
Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83–105.
pubmed: 19633992
pmcid: 19633992
Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs. 2010;24:843–66.
pubmed: 20839896
pmcid: 20839896
Lu Y, Sjolander A, Cederlof M, D’Onofrio BM, Almqvist C, Larsson H, et al. Association between medication use and performance on higher education entrance tests in individuals with attention-deficit/hyperactivity disorder. JAMA Psychiatry. 2017;74:815–22.
pubmed: 28658471
pmcid: 28658471
Chang Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry. 2017;74:597–603.
pubmed: 28492937
pmcid: 28492937
Liao YT, Yang YH, Kuo TY, Liang HY, Huang KY, Wang TN, et al. Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan. Eur Child Adolesc Psychiatry. 2018;27:279–88.
Man KK, Chan EW, Coghill D, Douglas I, Ip P, Leung LP, et al. Methylphenidate and the risk of trauma. Pediatrics. 2015;135:40–8.
pubmed: 25511122
pmcid: 25511122
Mikolajczyk R, Horn J, Schmedt N, Langner I, Lindemann C, Garbe E. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. JAMA Pediatr. 2015;169:391–5.
pubmed: 25686215
pmcid: 25686215
Swanson JM, Arnold LE, Molina BSG, Sibley MH, Hechtman LT, Hinshaw SP, et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry. 2017;58:663–78.
pubmed: 28295312
pmcid: 28295312
Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52:250–63.
pubmed: 23452682
pmcid: 23452682
Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008;165:604–9.
pubmed: 18381904
pmcid: 18381904
Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, et al. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry. 2005;162:1628–36.
pubmed: 16135621
pmcid: 16135621
van der Schans J, Kotsopoulos N, Hoekstra PJ, Hak E, Postma MJ. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate. PLoS ONE. 2015;10:e0127237.
pubmed: 26024479
pmcid: 26024479
Page TF, Pelham WE 3rd, Fabiano GA, Greiner AR, Gnagy EM, Hart KC, et al. Comparative cost analysis of sequential, adaptive, behavioral, pharmacological, and combined treatments for childhood ADHD. J Clin Child Adolesc Psychol. 2016;45:416–27.
pubmed: 26808137
pmcid: 26808137
Kon AA. The shared decision-making continuum. JAMA. 2010;304:903–4.
pubmed: 20736477
pmcid: 20736477
Tandon M, Pergjika A. Attention deficit hyperactivity disorder in preschool-age children. Child Adolesc Psychiatr Clin N Am. 2017;26:523–38.
pubmed: 28577607
pmcid: 28577607
Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1284–93.
pubmed: 17023867
pmcid: 17023867
Moriyama TS, Polanczyk GV, Terzi FS, Faria KM, Rohde LA. Psychopharmacology and psychotherapy for the treatment of adults with ADHD—a systematic review of available meta-analyses. CNS Spectr. 2013;18:296–306.
pubmed: 23739183
pmcid: 23739183
Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54:728–36.
pubmed: 26299294
pmcid: 26299294
Pringsheim T, Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2011;4:CD007990.
Cunill R, Castells X, Tobias A, Capella D. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol. 2015;29:15–23.
pubmed: 25142405
pmcid: 25142405
Perez de los Cobos J, Sinol N, Perez V, Trujols J. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol. 2014;77:337–56.
pubmed: 23216449
pmcid: 23216449
Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend. 2008;95:140–6.
pubmed: 18328639
pmcid: 18328639
Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:593–602.
pubmed: 25887096
pmcid: 25887096
Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH. Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015;25:611–7.
pubmed: 26402485
pmcid: 26402485
Brinkman WB, Epstein JN. Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences. Patient Prefer Adherence. 2011;5:45–56.
pubmed: 21311701
pmcid: 21311701
Kendall J, Hatton D, Beckett A, Leo M. Children’s accounts of attention-deficit/hyperactivity disorder. ANS Adv Nurs Sci. 2003;26:114–30.
pubmed: 12795540
pmcid: 12795540
Owens JS, Goldfine ME, Evangelista NM, Hoza B, Kaiser NM. A critical review of self-perceptions and the positive illusory bias in children with ADHD. Clin Child Fam Psychol Rev. 2007;10:335–51.
pubmed: 17902055
pmcid: 17902055
Rush AJ. Isn’t it about time to employ measurement-based care in practice? Am J Psychiatry. 2015;172:934–6.
pubmed: 26315984
pmcid: 26315984
Coghill D, Seth S. Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway. Child Adolesc Psychiatry Ment Health. 2015;9:52.
pubmed: 26587055
pmcid: 26587055
Murphy KR, Adler LA. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry. 2004;65:12–17.
pubmed: 15046530
pmcid: 15046530
Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003;42:1015–37.
pubmed: 12960702
pmcid: 12960702
Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996;35:1304–13.
pubmed: 8885584
pmcid: 8885584
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159–65.
pubmed: 16420712
pmcid: 16420712
Karam RG, Breda V, Picon FA, Rovaris DL, Victor MM, Salgado CA, et al. Persistence and remission of ADHD during adulthood: a 7-year clinical follow-up study. Psychol Med. 2015;45:2045–56.
pubmed: 25612927
pmcid: 25612927
Caye A, Swanson J, Thapar A, Sibley M, Arseneault L, Hechtman L, et al. Life span studies of ADHD-conceptual challenges and predictors of persistence and outcome. Curr Psychiatry Rep. 2016;18:111.
pubmed: 27783340
pmcid: 27783340
Caye A, Spadini AV, Karam RG, Grevet EH, Rovaris DL, Bau CH, et al. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry. 2016;25:1151–9.
Caye A, Sibley MH, Swanson JM, Rohde LA. Late-onset ADHD: understanding the evidence and building theoretical frameworks. Curr Psychiatry Rep. 2017;19:106.
pubmed: 29130145
pmcid: 29130145